Evidence map›Paper›PMID 36852093›Full record

ArticleOncoTargets and therapy2023

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report.

Meshaal Alanzi, Mohammad Abu-Tineh, Lajos Szabados, M Z Sharaf Eldean, Sali Alatasi, Ruba Y Taha, Sarah A Elkourashy

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Meshaal AlanziDepartment of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0001-7201-7010
Mohammad Abu-TinehDepartment of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, Qatar.ORCID 0000-0002-2984-0252
Lajos SzabadosDepartment of Nuclear Medicine, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
M Z Sharaf EldeanDepartment of Pathology, Hamad Medical Corporation, Doha, Qatar.
Sali AlatasiDepartment of Pathology, Hamad Medical Corporation, Doha, Qatar.
Ruba Y TahaDepartment of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, Qatar.
Sarah A ElkourashyDepartment of Medical Oncology/Hematology, National Center for Cancer Care and Research, Doha, Qatar.
National Center for Cancer Care and Research · QAHamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt's lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.

Indexed as

anti CD79bBurkitt’s lymphomaLymphomapolatuzumabresistant lymphoma

Identifiers

PMID36852093
PMCPMC9961566
OpenAlexW4321365990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.